Haemonetics Corp (HAE) Shares Up 10.58% on Nov 7

Author's Avatar
Nov 07, 2024

Shares of Haemonetics Corp (HAE, Financial) surged 10.58% in mid-day trading on Nov 7. The stock reached an intraday high of $87.37, before settling at $86.43, up from its previous close of $78.16. This places HAE 11.78% below its 52-week high of $97.97 and 23.03% above its 52-week low of $70.25. Trading volume was 464,409 shares, 80.1% of the average daily volume of 579,623.

Wall Street Analysts Forecast

1854558314298503168.png

Based on the one-year price targets offered by 10 analysts, the average target price for Haemonetics Corp (HAE, Financial) is $109.80 with a high estimate of $125.00 and a low estimate of $85.00. The average target implies an upside of 27.04% from the current price of $86.43. More detailed estimate data can be found on the Haemonetics Corp (HAE) Forecast page.

Based on the consensus recommendation from 10 brokerage firms, Haemonetics Corp's (HAE, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Based on GuruFocus estimates, the estimated GF Value for Haemonetics Corp (HAE, Financial) in one year is $100.34, suggesting a upside of 16.09% from the current price of $86.43. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Haemonetics Corp (HAE) Summary page.

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.